المؤلفون: Т. В. Мартынюк, З. Х. Дадачева, И. Е. Чазова

المصدر: Атеротромбоз, Vol 0, Iss 1, Pp 87-98 (2015)

مصطلحات موضوعية: легочная гипертензия, хроническая тромбоэмболическая легочная гипертензия, тромбэндартерэктомия, бозентан, простаноиды, силденафил, риоцигуат, Internal medicine, RC31-1245

وصف الملف: electronic resource

Relation: https://www.aterotromboz.ru/jour/article/view/10; https://doaj.org/toc/2307-1109; https://doaj.org/toc/2658-5952

URL الوصول: https://doaj.org/article/d67a9903c05c411888a3e6666cda8351

المؤلفون: И. Е. Чазова, С. Н. Наконечников

المصدر: Рациональная фармакотерапия в кардиологии, Vol 4, Iss 2 (2016)

مصطلحات موضوعية: Therapeutics. Pharmacology, RM1-950, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

Relation: https://www.rpcardio.com/jour/article/view/1102; https://doaj.org/toc/1819-6446; https://doaj.org/toc/2225-3653

URL الوصول: https://doaj.org/article/f659adf2de0e4cbda384a9acb4fb7a98

المؤلفون: D. V. Pevzner, N. S. Kostritca, A. K. Alieva, I. A. Merkulova, I. S. Yavelov, E. V. Merkulov, I. E. Chazova, Д. В. Певзнер, Н. С. Кострица, А. К. Алиева, И. A. Меркулова, И. С. Явелов, Е. В. Меркулов, И. Е. Чазова

المساهمون: The study was performed with the support of the National Medical Research Centre of Cardiology named after academician E.I. Chazov., Исследование проведено при поддержке Национального медицинского исследовательского центра кардиологии имени академика Е.И. Чазова.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 18, No 4 (2022); 439-448 ; Рациональная Фармакотерапия в Кардиологии; Vol 18, No 4 (2022); 439-448 ; 2225-3653 ; 1819-6446

مصطلحات موضوعية: кардиоэмболические осложнения, left atrial appendage occluder, direct oral anticoagulants, cardioembolic complications, окклюдер ушка левого предсердия, прямые оральные антикоагулянты

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2795/2344; Virani, SS, Alonso A, Benjamin EJ, et al. Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association. Circulation. 2020;141(9):e139-e596. DOI:10.1161/cir.0000000000000757.; Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-88. DOI:10.1161/01.str.22.8.983.; Gabet A, Guenancia C, Duloquin G, Olie V, Bejot Y Ischemic Stroke With Atrial Fibrillation: Characteristics and Time Trends 2006 to 2017 in the Dijon Stroke Registry. Stroke. 2021;52(6):2077-85. DOI:10.1161/STROKEAHA.120.030812.; Odell JA, Blackshear JL, Davies E, et al. Thoracoscopic obliteration of the left atrial appendage: Potential for stroke reduction? Ann Thorac Surg. 1962;61(2):565-9. DOI:10.1016/0003-4975(95)00885-3.; Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373-498. DOI:10.1093/eurheartj/ehaa612.; January ST, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol. 2019;74(1):104-32. DOI:10.1016/j.jacc.2019.01.011.; Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiortiy trial. Lancet. 2009;374(9689):534-42. DOI:10.1016/S0140-6736(09)61343-X.; Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1-12. DOI:10.1016/j.jacc.2014.04.029.; Osmancik P, Herman D, Neuzil P, et al. PRAGUE-17 Trial Investigators. Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation. J Am Coll Cardiol. 2020;75(25):3122-35. DOI:10.1016/j.jacc.2020.04.067.; Glikson M, Wolff R, Hindricks G, et al. ESC Scientific Document Group. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. Europace. 2020;22(2):184. DOI:10.1093/europace/euz258.; Franco L, Becattini C, Beyer-Westendorf J, et al. Definition of major bleeding: Prognostic classification. J Thromb Haemost. 2020;18(11):2852-60. DOI:10.1111/jth.15048.; Reddy VY, Sievert H, Halperin J, et al. PROTECT AF Steering Committee and Investigators. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. J Am Med Assoc. 2014;312(19):1988-98. DOI:10.1001/jama.2014.15192.; Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. DOI:10.1056/NEJMoa0905561.; Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in non-valvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91. DOI:10.1056/NEJMoa1009638.; Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. DOI:10.1056/NEJMoa1107039.; Giugliano RP, Ruff CT, Braunwald E, et al. ENGAGE AF-TIMI Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-104. DOI:10.1056/NEJMoa1310907.; Connolly S, Pogue J, Hart R, et al. ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903-12. DOI:10.1016/S0140-6736(06)68845-4.; Mant J, Hobbs FD, Fletcher K, et al. BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493-503. DOI:10.1016/S0140-6736(07)61233-1.; Reddy VY, Doshi SK, Kar S, et al. PREVAIL and PROTECT AF Investigators. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. J Am Coll Cardiol. 2017;70(24):2964-75. DOI:10.1016/j.jacc.2017.10.021.; Давтян К.В., Калемберг А.А., Симонян Г.Ю. Эффективность профилактики ишемического инсульта у пациентов с имплантированным окклюзирующим устройством ушка левого предсердия. Результаты пятилетнего наблюдения. Российский Кардиологический Журнал. 2018;(7):16-20. DOI:10.15829/1560-4071-2018-7-16-20.; Turagam MK, Osmancik P, Neuzil P, et al. Left atrial appendage closure versus oral anticoagulants in atrial fibrillation: a meta-analysis of randomized trials. J Am Coll Cardiol. 2020;76(23):2795-7. DOI:10.1016/j.jacc.2020.08.089.; Boersma LV, Schmidt B, Betts TR, et al. EWOLUTION investigators. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J. 2016;37(31):2465-74. DOI:10.1093/eurheartj/ehv730.; Шугушев Э.Х., Родионова Л.В., Ганеева О.Н., и др. Непосредственные и отдаленные результаты имплантации окклюдера ушка левого предсердия у больных с фибрилляцией предсердия. Российский Кардиологический Журнал. 2020;(12):28-32. DOI:10.15829/1560-4071-2016-12-28-32.; Tzikas A, Shakir S, Gafoor S et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention. 2016;11(10):1170-9. DOI:10.4244/EIJY15M01_06.; https://www.rpcardio.com/jour/article/view/2795

الاتاحة: https://www.rpcardio.com/jour/article/view/2795
https://doi.org/10.20996/1819-6446-2022-08-09

المؤلفون: S. N. Avdeev, N. A. Tsareva, G. V. Nekludova, I. E. Chazova, A. G. Chuchalin, С. Н. Авдеев, Н. А. Царева, Г. В. Неклюдова, И. Е. Чазова, Л. Г. Чучалил

المصدر: PULMONOLOGIYA; № 4 (2001); 34-39 ; Пульмонология; № 4 (2001); 34-39 ; 2541-9617 ; 0869-0189

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/2849/2260; Rabin L.J. АССР Consensus Statement: primiry pulmonary hypertension. Chest 1993; 104: 236—250.; Brij S., Peacock A.J. Pulmonary hypertension: its assessment and treatment. Thorax 1999; 54 (suppl.2): S28—S32.; Groechenig E. Cor pulmonale. Treatment of pulmonary hypertension. Blackwell Science, Berlin—Vienna, 1999; pp 146.; Чазова И.Е. Современные подходы к лечению легочного сердца. Рус. мед. журн. 2000; 8 (2): 83—86.; Rich S., Dantzker D.R., Agrès S.M. Primary pulmonary hypertension: a national prospective study. Ann. Intern. Med. 1987; 107: 216—223.; Pepke-Zaba I., Higgenbottam T.W., Dinnh-Xuan A.T. et al. Inhaied nitric oxide as a cause of sélective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991; 338: 1173—1174.; Чучалин A .Г., Авдеев С.М., Царева И.А., Неклюдова Г.В., Науменко Ж.К., Черняев A.JI. Применение ингаляции оксида азота при первичной легочной гипертензии. Рус. мед. журн. 2001: 9 (1): 35—37.; Sitbon О., Humbert М ., Jagot J. et at. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calciumchannel blockers in primary pulmonary hypertension. Eur. Respir. J. 1998; 12: 265—270.; Channick R.N., Newhart J.W., Johnson F.W. el al. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension. An ambulatory delivery system and initial clinical tests. Chest 1996; 109: 1545—1549.; Weir E.K., Rubin L.J., Ayres S.M. et al. The acute administration of vasodilators in primary pulmonary hypertension. Am. Rev. Respi. Dis. 1989; 140: 1623—1630.; Quanjer Ph.H., Tammeling G.J., Cotes J.E. et al. Lung volumes and forced ventilatory flows. Eur. Respir. J. 1993; 6 (suppl.l6): 5—40.; Cotes J.E., Chinn D.J., Quanjer Ph.H. et al. Standartization of the measurement of transfer factor (diffusing capacity). Eur. Respir. J. 1993; 6 (suppl. 16): 41—52.; Kitabatake A., I noue М., Asao M. et al. Noninvasive evaluation of pulmonary hypertension by a pulsed doppler technique. Circulation 1983; 68: 302—309.; Berger М., Haimovitz A., Van Tosh A. et al. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J. Am. Coll. Cardiol. 1985; 6: 359—365.; Kirshir iS., Himelman R.B., Schiller М.В . Right atrial pressure estimation in respiratory behavior of the inferior vena cava. Circulation 1988; 78: II—550 (2196).; Enright P.L., Sherill D.L. Reference equations for the six-minute walk in healthy adults. Am. J. Respir. Crit. Care Med. 1998; 158: 1384—1387.; Palmer R.M., Ferridge A.G., Moncada S. Nitric oxide accounts for the biological activity of endothelium derived relaxing factor. Nature. 1987; 327: 524—526.; Ignarro L.J., Buga G.M., Wood K.S. et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. USA 1987; 84: 9265—9269.; Ignarro L.J. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ. Res. 1989; 65: 1—21; Siddons T.E., Asif М., Higenbottam T.W. Therapeutic role of nitric oxide in respiratory disease. Medscape 2000; 4 (2), Inc.; Jolliet P., Bulpa P., Thorens J.-B., Ritz M., Chevrolet J.-C. Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: predictive ability and consequences on haemodynamics and gas exchange. Thorax 1997; 52: 369—372; Loh E., Stamler J.S., Hare J.M. et al. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation 1994; 90: 2780—2785.; Cockrill B.A., Kacmarek R.M., Fifer M.A. et al. Comparison of the effects of nitric oxide, nitroprusside, and nifedipine on hemodynamics and right ventricular contractility in patients with chronic pulmonary hypertension. Chest 2001; 119: 128—136.; Puybasset L., Rouby J.-J., Mourgeon E. et al. Factors influencing cardiopulmonary effects of inhaied nitric oxide in acute respiratory failure. Am. J. Respir. Crit. Care Med. 1995; 152: 318—328.; Hopkins S.R., Johnson E.C., Richardson R.S. et al. Effects of inhaled nitric oxide on gas exchange in lungs with shunt or poorly ventilated areas. Am. J. Respir. Crit. Care Med. 1997; 156: 484—491.; Koh E., Niimura J., Nakamura T. et al. Long-term inhalation of nitric oxide for a Datient with primary pulmonary hypertension. Jpn. Circ. J. 1998; 62: 940—942.; Perez-Penate G., Julia-Serda G., Pulido-Duque J.M. et al. One-year continuous inhaled nitric oxide for primary pulmonary hypertension. Chest 2001; 119: 970—973.; Gibbons G.H. Endothelial function as a determinant of vascular function and structure: A new therapeutic target. Am. J. Cardiol. 1997; 79: 3—8.; https://journal.pulmonology.ru/pulm/article/view/2849

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/2849

المؤلفون: M. B. Karabasheva, N. M. Danilov, O. V. Sagaydak, D. I. Darensky, V. K. Lazutkina, I. E. Chazova, М. Б. Карабашева, Н. М. Данилов, О. В. Сагайдак, Д. И. Даренский, В. К. Лазуткина, И. Е. Чазова

المصدر: Siberian Journal of Clinical and Experimental Medicine; Том 34, № 3 (2019); 172-178 ; Сибирский журнал клинической и экспериментальной медицины; Том 34, № 3 (2019); 172-178 ; 2713-265X ; 2713-2927 ; 10.29001/2073-8552-2019-34-3

مصطلحات موضوعية: хроническая сердечная недостаточность, pulmonary hypertension, alveolar hypoventilation, phosphodiesterase type 5 inhibitor, chronic heart failure, легочная гипертензия, альвеолярная гиповентиляция, ингибитор фосфодиэстеразы 5-го типа

وصف الملف: application/pdf

Relation: https://www.sibjcem.ru/jour/article/view/829/483; Galiè N., Humbert M., Vachiery J.L., Gibbs S., Lang I., Torbicki A. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur. Heart J. 2016;37(1):67–119. DOI:10.1093/eurheartj/ehv317.; Bergofsky E.H., Turino G.M., Fishman A.P. Cardiorespiratory failure in kyphoscoliosis. Medicine. 1959;38:263–318.; Berger R.M., Beghetti M., Humpl T., Raskob G.E., Ivy D.D., Jing Z.C. et al. Clinical features of pediatric pulmonary hypertension: A registry study. Lancet. 2012;379:537–546. DOI:10.1016/S0140-6736(11)61621-8.; Hurdman J., Condliffe R., Elliot C.A., Davies C., Hill C., Wild J.M. et al. ASPIRE registry: Assessing the spectrum of pulmonary hypertension indented at a REferral centre. Eur. Respir. J. 2012;39:945–955. DOI:10.1183/09031936.00078411.; Chaouat A., Weitzenblum E., Krieger J., Oswald M., Kessler R. Pulmonary hemodynamics in the obstructive sleep apnea syndrome: Results in 220 consecutive patients. Chest. 1996;109:380–386. DOI:10.1378/chest.109.2.380.; Turino G.M., Goldring R.M., Fishman A.P. Cor pulmonale in musculoskeletal abnormalities of the thorax. Bull. NY Acad. Med. 1965;41:959–980.; Sawicka E.H., Branthwaite M.A. Respiration during sleep in kyphoscoliosis. Thorax. 1987;42:801–808. DOI:10.1136/thx.42.10.801.; Smith I.E., Laroche C.M., Jamieson S.A., Shneerson J.M. Kyphosis secondary to tuberculosis osteomyelitis as a cause of ventilatory failure: Clinical features, mechanisms and management. Chest. 1996;110:1105–1110.; Nauffal D., Domènech R., Martínez García M.A., Compte L., Macián V., Perpiñá M. Noninvasive positive pressure home ventilation in restrictive disorders: Outcome and impact on health-related quality of life. Respir. Med. 2002;96:777–783.; https://www.sibjcem.ru/jour/article/view/829

الاتاحة: https://www.sibjcem.ru/jour/article/view/829
https://doi.org/10.29001/2073-8552-2019-34-3-172-178

المؤلفون: A. V. Aksenova, E. V. Oshchepkova, A. A. Orlovsky, I. E. Chazova, А. В. Аксенова, Е. В. Ощепкова, А. А. Орловский, И. Е. Чазова

المصدر: Siberian Journal of Clinical and Experimental Medicine; Том 34, № 3 (2019); 73-86 ; Сибирский журнал клинической и экспериментальной медицины; Том 34, № 3 (2019); 73-86 ; 2713-265X ; 2713-2927 ; 10.29001/2073-8552-2019-34-3

مصطلحات موضوعية: гиполипидемическая терапия, aging patients, older patients, elderly, guidelines for the management of arterial hypertension, target blood pressure, antihypertensive treatment, lipid-lowering treatment, пациенты пожилого и старческого возраста, клинические рекомендации по лечению артериальной гипертонии, целевые уровни АД, антигипертензивная терапия

وصف الملف: application/pdf

Relation: https://www.sibjcem.ru/jour/article/view/816/472; Asayama K., Li Y., Franklin S.S., Thijs L., O’Brien E., Staessen J.A. Cardiovascular risk associated with white-coat hypertension: on side of the argument. Hypertension. 2017;70(4):676–682. DOI:10.1161/HYPERTENSIONAHA.117.08902.; Williams B. Resistant hypertension: an unmet treatment need. Lancet. 2009;24;374(9699):1396–1398. DOI:10.1016/S0140-6736(09)61600-7.; Kjeldsen S.E., Stenehjem A., Os I., van de Borne Ph., Burnier M., Narkiewicz K. et al. Treatment of high blood pressure in elderly and octogenarians: European Society of Hypertension statement on blood pressure targets. Blood Press. 2016;25(6):333–336. DOI:10.1080/08037051.2016.1236329.; Corrao G., Mazzola P., Compagnoni M.M., Rea F., Merlino L., Annoni G. et al. Antihypertensive мedications, loop diuretics, and risk of hip fracture in the elderly: a population-based cohort study of 81,617 italian patients newly treated between 2005 and 2009. Drugs Aging. 2015;32(11):927–936. DOI:10.1007/s40266-015-0306-5.; Williams B., Mancia G., Spiering W., Adabiti Rosei E., Azizi M., Burnier M. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur. Heart J. 2018;39(33):3021–3104. DOI:10.1093/eurheartj/ehy339.; Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019;16(1):6–31. DOI:10.26442/2075082X.2019.1.190179.; Beckett N.S., Peters R., Fletcher A.E., Staessen J.A., Liu L., Dumitrascu D. et al. Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 2008;358(18):887–898. DOI:10.1056/nejmoa0801369.; Briasoulis A., Agarwal V., Tousoulis D., Stefanadis C. Effects of antihypertensive treatment in patients over 65 years of age: a meta-analysis of randomised controlled studies. Heart. 2014;100(4):317–323. DOI:10.1136/heartjnl-2013-304111.; Acelajado M.C. Optimal management of hypertension in elderly patients. Integr. Blood Press Control. 2010;3:145–153. DOI:10.2147/IBPC.S6778.; Mortensen M.B., Falk E. Primary рrevention with statins in the elderly. J. Am. Coll. Cardiol. 2018;71(1):85–94 DOI:10.1016/j.jacc.2017.10.080.; Savarese G., Gotto J.R., Paolillo S., D’Amore C., Losco T., Musella F. et al. Erratum: benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J. Am. Coll. Cardiol. 2013;62:2090–2099. DOI:10.1016/j.jacc.2014.02.534.; Glynn R.J., Koenig W., Nordestgaard B.G., Shepherd J., Ridker P.M. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann. Intern. Med. 2010;152(8):488–496. DOI:10.7326/0003-4819-152-8-201004200-00005.; Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., Bhala N. et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681. DOI:10.1016/S0140- 6736(10)61350-5.; Ощепкова Е.В., Лазарева Н.В., Чазова И.Е. Оценка качества обследования больных артериальной гипертонией в первичном звене здравоохранения (по данным российского Регистра артериальной гипертонии). Журнал «Системные гипертензии». 2017;14(2):29– 34. DOI:10.26442/2075-082X_14.2.29-34.; Thomopoulos C., Parati G., Zanchetti A. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J. Hypertens. 2017;35(11):2150–2160. DOI:10.1097/HJH.0000000000001547.; Savarese G., Dahlström U., Vasko P., Pitt B., Lund L.H. Association between renin-angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study. Eur. Heart. J. 2018;39(48):4257–4265. DOI:10.1093/eurheartj/ehy621.; Рекомендации ЕОК по ведению пациентов с острым инфарктом миокарда с подъемом сегмента ST 2017. Российский кардиологический журнал. 2018;5:103–158. DOI:10.15829/1560-4071-2018-5-103-158.; Ponikowski P., Voors А.A., Anker S.D, Bueno H., Cleland J.G.F., Coats A.J.S. et al. Рекомендации ESH по диагностике и лечению острой и хронической сердечной недостаточности 2016. Российский кардиологический журнал. 2017;1:7–81. DOI:10.15829/1560-4071-2017- 1-7-81.; Freeman R., Wieling W., Axelrod F.B., Benditt D.G., Benarroch E., Biaggioni I. et al. Consensus statement on the definition of orthostatic hypotension, neutrally mediated syncope and the postural tachycardia syndrome. Clin. Auton. Res. 2011;21:69–72. DOI:10.1007/s10286-011-0119-5.; https://www.sibjcem.ru/jour/article/view/816

الاتاحة: https://www.sibjcem.ru/jour/article/view/816
https://doi.org/10.29001/2073-8552-2019-34-3-73-86